Verve Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Verve Therapeutics, a clinical-stage biotechnology firm, focuses on innovative gene editing therapies for cardiovascular diseases. CEO Sekar Kathiresan will present at two investor conferences: the Jefferies London Healthcare Conference on November 15, 2022, and the Evercore ISI Virtual HealthCONx Conference on November 29, 2022. These events will be broadcast live and archived for 60 days. Notably, their programs VERVE-101 and VERVE-201 aim to lower LDL cholesterol levels by targeting specific genes, potentially transforming chronic care into a single treatment solution.

BOSTON, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will participate in fireside chats during the following upcoming investor conferences:

• Jefferies London Healthcare Conference on Tuesday, November 15, 2022, at 1:30 p.m. GMT in London; and,
• Evercore ISI Virtual HealthCONx Conference 2022 on Tuesday, November 29, 2022, at 8:50 a.m. ET.

Live webcasts of the events will be available in the investor section of the company's website at www.vervetx.com, and will be archived for 60 days following the presentations.

About Verve Therapeutics
Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage genetic medicines company pioneering a new approach to the care of cardiovascular disease, potentially transforming treatment from chronic management to single-course gene editing medicines. The company’s initial two programs – VERVE-101 and VERVE-201 – target genes that have been extensively validated as targets for lowering low-density lipoprotein cholesterol (LDL-C), a root cause of cardiovascular disease, in order to durably reduce blood LDL-C levels. VERVE-101 is designed to permanently turn off the PCSK9 gene in the liver and is being developed initially for heterozygous familial hypercholesterolemia (HeFH) and ultimately to treat atherosclerotic cardiovascular disease (ASCVD) patients not at goal on oral therapy. VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed in homozygous familial hypercholesterolemia (HoFH) and ultimately to treat patients with ASCVD who have not achieved goal LDL-C with oral therapy and a PCSK9 inhibitor. For more information, please visit www.VerveTx.com

Investor Contact
Jen Robinson
Verve Therapeutics, Inc.
jrobinson@vervetx.com

Media Contact
Ashlea Kosikowski
1AB
ashlea@1abmedia.com

FAQ

When will Verve Therapeutics participate in the Jefferies London Healthcare Conference?

Verve Therapeutics will present at the Jefferies London Healthcare Conference on November 15, 2022, at 1:30 p.m. GMT.

What is the focus of Verve Therapeutics' gene editing medicines?

Verve Therapeutics focuses on gene editing therapies aimed at treating cardiovascular diseases by lowering LDL cholesterol levels.

How can I watch the live presentations from Verve Therapeutics?

Live webcasts of Verve Therapeutics' presentations will be available in the investor section of their website.

What are the main programs of Verve Therapeutics?

The main programs of Verve Therapeutics are VERVE-101, targeting the PCSK9 gene, and VERVE-201, targeting the ANGPTL3 gene.

What is the purpose of the VERVE-101 program?

The VERVE-101 program aims to permanently turn off the PCSK9 gene to lower LDL cholesterol levels in patients with familial hypercholesterolemia.